Imatron reports record EBCT sales revenue
Rising sales of its proprietary electron-beam computed tomography scanner sent Imatron’s sales soaring during the second fiscal quarter of 2000. Revenue for the three months ending June 30 was $15.5 million, an increase of 87% over revenue of $8.3
Rising sales of its proprietary electron-beam computed tomography scanner sent Imatrons sales soaring during the second fiscal quarter of 2000. Revenue for the three months ending June 30 was $15.5 million, an increase of 87% over revenue of $8.3 million for the same period a year earlier, the company announced.
Net income for the same three-month period increased $3 million to $1 million, compared to a net loss of $1.9 million for the same period a year ago. Second-quarter revenue increased 37% and net income increased 321% over Imatrons first quarter, end March 31, 2000.
Imatron has shown rising sales of its scanners (which the company calls simply EBT) in the U.S. and abroad. The firm is investing in development of an international sales staff to increase business in Japan, China, Germany, and the Middle East (SCAN, 7/5/00).
The primary use of Imatron scanners has been to detect coronary artery calcium, a technique that has been called into question in a joint statement by the American College of Cardiology and the American Heart Association for the shortage of conclusive studies on its efficacy. Imatrons defenders, in turn, criticized the consensus paper.
So far, the controversy has not dampened Imatrons sales.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
